Kevin Sharer - Amgen

Kevin Sharer - Amgen
Total Compensation: $18.9 million

Details: After drawing the ire of investors for the company's flagging stock price and steep R&D costs, Sharer is set to retire May 23, after 20 years with Amgen ($AMGN). He took yet another pay cut in 2011, seeing his total compensation fall by more than $2 million, thanks mostly to a more than 50% reduction in option awards from 2010.

Sharer's decade in charge at Amgen saw excellent growth, going from $3.6 billion in revenue to more than $16 billion. However, safety concerns over the company's anemia treatments led to some big losses in the last few years, and the 63-year-old's name has a tendency to pop up on lists of the industry's most overpaid execs. But the news isn't all bad for Sharer. As Dow Jones reported earlier this year, the soon-to-be-ex CEO is likely in line for a $49 million retirement package once he steps down--not William Weldon money, to be sure, but probably enough for some comfortable golden years.

Editor's Note: Sharer's retirement package includes accumulated retirement plan contributions and benefits, and deferred compensation. It also includes stock awards and options.

Kevin Sharer - Amgen
Read more on

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.